Prothrombin Complex Concentrate PCC Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Prothrombin Complex Concentrate PCC Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Growth Factors of Prothrombin Complex Concentrate Market

The prothrombin complex concentrate market size was valued at USD 695.3 million in 2019, and the market is now projected to grow from USD 695.3 million in 2019 to USD 2385.3 million by 2032, exhibiting a CAGR of 9.6% during the forecast period of 2019-2032.

Pandemic has heightened call for blood and plasma merchandise, main to adjustments in plasma-derived product buying patterns. Major PCC manufacturers, along with Grifols and CSL, are experiencing increased segmental revenue due to increased plasma center productiveness and Kcentra's double-digit growth, that is expected to positively impact the overall market.

PCC is a popular anticoagulation-reversal remedy because of its benefits over other options like FFP and Vitamin Kl. It eliminates the need for blood matching and thawing, reducing management time. PCC offers shorter penetration time, better performance, and is needed in much less quantity. It also has minimal hazard of viral or pathogen transmission, making it a favored choice and doubtlessly contributing to marketplace expansion. These benefits have brought about increased choice for PCC in pressing warfarin-reversals.

The marketplace trend is that specialize in increasing plasma facilities, main to improved manufacturing techniques for plasma proteins. Major players are acquiring home companies to gain from their plasma centers and decorate manufacturing capacity. Grifols S.A. Is expected to benefit get access to Biotest's plasma collection centers and boom its plasma protein deliver for healing purposes. The growth in manufacturing and delivery of thing IX complex, in particular in the course of the COVID-19 pandemic, is predicted to boost the prothrombin complex concentrate market growth.

Comprehensive Analysis of Prothrombin Complex Concentrate Market

The PCC market segment is divided into 3-factor PCC and 4-factor PCC, with the 4-factor segment accounting for the majority in 2019. The 4-factor segment is driven by improved penetration of 4-factor PCC brands like Kcentra & Beriplex in emerging countries and their clinically proven efficacy for urgent warfarin reversal. The 3-factor segment is expected to grow due to the rising prevalence of hemophilia and increasing demand for Profilnine SD and Bebulin. The market is also segmented into acquired coagulation factor deficiency and congenital coagulation factor deficiency. The acquired coagulation factor deficiency segment generated the highest revenue in 2019 and is expected to experience significant growth due to increasing cases of life-threatening bleeding, induced coagulation factor deficiency during surgical procedures, and new product launches. The congenital coagulation factor deficiency segment is expected to gain momentum due to increased sales of Kcentra during the COVID-19 crisis. The end user segment is primarily hospitals and ambulatory surgical centres, with hospitals and ambulatory surgery expected to dominate the market due to rising demand for prothrombin complex concentrate, government recommendations, and increased plasma product purchases. Specialty clinics are expected to grow due to the increasing number of surgeons and privately owned clinics. The others segment, including urgent care centres, emergency trauma centres, and physicians' offices, is likely to grow due to increased investment in healthcare facilities.

The North America region lead the prothrombin complex concentrate market share by benefitting a market size of USD 305.9 million in 2019 due to aid of essential manufacturers' strategic presence, the USFDA's green sign for 4-factor PCC, and Kcentra's increasing income. Canada's buy of 3,728,656 1. U of element IX in 2018 is expected to similarly raise the marketplace in North America.

CSL Behring holds the largest market share in sales due to Kcentra sales. In 2017, it released Kcentra in Japan, with round 2,800 sufferers the usage of it in 2019. Key corporations consist of Grifols, S.A., CSL Behring, Octopharma AG, Sanquin, Kedrion S.P.A, China Biologic Products Holdings, Inc., and Takeda Pharmaceutical Company Limited.

In March 2019, Grifols S.A. Entered a strategic agreement to govern 26.2% of Shanghai RAAS in trade for a non-minority share in Grifols Diagnostic Solutions, aiming to enhance its plasma-derived merchandise in China.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2016-2027

Base Year 2019

Forecast Period 2020-2027

Historical Period 2016-2018

Unit Value (USD million)

By Product Type

3-factor

4-factor

By Application

Acquired Coagulation Factor Deficiency

Congenital Coagulation Factor Deficiency

By End User

Hospital & Ambulatory Surgical Centers

Specialty Clinics

Others

By Geography

North America (the U.S. and Canada)

Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia- Pacific)

Latin America (Brazil, Mexico, and Rest of Latin America)

The Middle East& Africa (South Africa, GCC, and Rest of the Middle East & Africa)

Please Note: It will take 5-6 business days to complete the report upon order confirmation.